



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

OCT 14 2008

Daniel J. Hulseberg
BAKER BOTTS LLP
30 Rockefeller Plaza
New York, NY 10112-4498

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,451,233

Dear Mr. Hulseberg :

An interim extension under 35 U.S.C. § 156(e)(2) is enclosed extending the term of U.S. Patent No. 5,451,233 for a period of 1 year. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any changes to patent expiration dates that FDA may require.

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: XIENCE™ V EECSS
(everolimus eluting coronary
stent system)
FDA Docket No.:

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE


In re Abbott Cardiovascular Systems, Inc. :
Request for Patent Term Extension : ORDER GRANTING
U.S. Patent No. 5,451,233 : INTERIM EXTENSION

On July 25, 2008, Abbott Cardiovascular Systems, Inc., an agent of Paul G. Yock, the owner of record in the United States Patent and Trademark Office (USPTO) of U.S. Patent No. 5,451,233, filed an application for patent term extension under 35 U.S.C. § 156. The original term of the patent is due to expire on October 29, 2008. The patent claims the medical device XIENCE™ V EECSS (everolimus eluting coronary stent system), which was approved by the Food and Drug Administration for commercial marketing or use on July 2, 2008. An extension of 937 days is requested.

The initial USPTO review of the application to date indicates that the subject patent is eligible for extension of the patent term under 35 U.S.C. § 156. A final determination of the length of the extension of the patent term and issuance of a patent term extension certificate cannot be made until a final determination of the length of the regulatory review period is made. Because the original term of the patent would expire before a certificate of patent term extension can be issued, an interim extension of the patent term is appropriate.

An interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 5,451,233 is granted for a period of one year from the original expiration date of the patent.

10/10/08
Date



Jon W. Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office